Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
- PMID: 37307560
- DOI: 10.1111/apt.17537
Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
Comment in
-
Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply.Aliment Pharmacol Ther. 2023 Jul;58(1):145-146. doi: 10.1111/apt.17552. Aliment Pharmacol Ther. 2023. PMID: 37307554 No abstract available.
Comment on
-
Systematic review-pancreatic involvement in inflammatory bowel disease.Aliment Pharmacol Ther. 2022 Jun;55(12):1478-1491. doi: 10.1111/apt.16949. Epub 2022 May 3. Aliment Pharmacol Ther. 2022. PMID: 35505465 Free PMC article.
References
REFERENCES
-
- Everhov ÅH, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, et al. Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017. Aliment Pharmacol Ther. 2020;52(1):143-54.
-
- Massironi S, Fanetti I, Viganò C, Pirola L, Fichera M, Cristoferi L, et al. Systematic review-pancreatic involvement in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(12):1478-91.
-
- Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a Nationwide population-based study. J Crohns Colitis. 2017;11(8):954-62.
-
- Lo B, Zhao M, Vind I, Burisch J. The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2021;19(6):1117-38.e19.
-
- Gormley M, Dudding T, Thomas SJ, Tyrrell J, Ness AR, Pring M, et al. Evaluating the effect of metabolic traits on oral and oropharyngeal cancer risk using Mendelian randomization. Elife. 2023;12:12.
Publication types
MeSH terms
LinkOut - more resources
Medical